EP0258118B1 - Procédé de stabilisation d'un plasmide contenu dans une souche bactérienne et souche obtenue - Google Patents

Procédé de stabilisation d'un plasmide contenu dans une souche bactérienne et souche obtenue Download PDF

Info

Publication number
EP0258118B1
EP0258118B1 EP87401815A EP87401815A EP0258118B1 EP 0258118 B1 EP0258118 B1 EP 0258118B1 EP 87401815 A EP87401815 A EP 87401815A EP 87401815 A EP87401815 A EP 87401815A EP 0258118 B1 EP0258118 B1 EP 0258118B1
Authority
EP
European Patent Office
Prior art keywords
gene
dapd
plasmid
expression
strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP87401815A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0258118A1 (fr
Inventor
Eric Degryse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR8611311A external-priority patent/FR2602792B1/fr
Priority claimed from FR8709935A external-priority patent/FR2618159B2/fr
Application filed by Transgene SA filed Critical Transgene SA
Publication of EP0258118A1 publication Critical patent/EP0258118A1/fr
Application granted granted Critical
Publication of EP0258118B1 publication Critical patent/EP0258118B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/68—Stabilisation of the vector

Definitions

  • the cloning and expression vectors commonly used in the laboratory are generally multicopy plasmids and their stable transmission to the offspring is ensured by the large number of plasmids per cell genome (Jones et al. 1980).
  • the introduction of foreign genes into these plasmids leads to varying degrees of instability during the bacteria's multiplication cycles.
  • industrial productions may require cultures of 1000 liters, resulting in more than 1016 cells, after more than 50 generations. It is therefore essential to stabilize the plasmids in the bacteria to ensure their presence and therefore the expression of the foreign molecule, until the end of the culture in a fermenter.
  • the host cell is mutated (auxotrophic mutation or introduction of a lethal gene for the bacteria) so as to prevent its multiplication in the absence of a plasmid coding for a character which complements the host's deficiency.
  • Diaminopimelic acid is a component of the bacteria wall; it also constitutes an intermediary in the biosynthesis of lysine from aspartate.
  • a strain deficient in an enzyme of the biosynthesis of DAP will not be able to multiply in minimum medium; the addition of lysine to the medium will allow growth but will rapidly lead to the lysis of the cell which does not incorporate DAP into its membrane (Work 1950 - Davis et al., 1973).
  • the deficiency of an enzyme in the biosynthesis of DAP can be supplemented by the introduction of the corresponding gene on a plasmid and, in particular, on the expression vector of the foreign protein whose production is to be ensured. If the bacteria lose the plasmid, it becomes dap ⁇ again and can no longer multiply.
  • This model has the advantage of being able to apply to any culture medium devoid of DAP, that is to say any industrial medium this production and any medium rich or minimum added with lysine.
  • the system also has the advantage of not disturbing the synthesis of DNA, RNA or proteins.
  • dapD ⁇ strain (deleted from one of the 9 genes of the lysine biosynthetic pathway, the D gene, corresponding to tetrahydropicolinate-N-succinyl transferase) and introduced the dapD gene on a commonly used expression plasmid (carrying the gene to be expressed under the control of the promoter P L ). Under selection conditions, it can be shown that the plasmid is stable for at least 150 generations.
  • the E. coli dapD gene has already been cloned into the plasmid pBR322 and its nucleotide sequence has been published by Richaud et al. (1984) but the aim of this work is only the study of the regulation of this gene.
  • the present invention relates to a method for stabilizing a plasmid vector contained in a bacterium, characterized in that the bacterium comprises a chromosomal mutation dap ⁇ and in that the plasmid vector carries a dap+ gene.
  • dapD ⁇ chromosomal mutations
  • other genes coding for an enzyme of the biosynthesis of DAP could be used provided that a vector plasmid carrying the corresponding gene is provided; in the case of a dapD ⁇ strain, the gene to be inserted into the plasmid will be dapD.
  • the present invention more specifically relates to a bacterial strain comprising a mutation in the dapD gene and transformed by a plasmid vector carrying an intact dapD gene, as well as a gene coding for a protein of interest, and the elements ensuring its expression in the host bacteria.
  • the dap stabilization system does not interfere with the expression of the protein, it can therefore be used with any expression vector,
  • the present invention relates more particularly to a strain as described above, characterized in that the chromosomal mutation dap is a deletion of at least part of the dapD gene and in that the plasmid vector carries an intact dapD gene.
  • Cyclone (Summers and Sherratt, 1984) is an element which does not code for any protein and whose presence promotes the monomeric maintenance of a plasmid. If the plasmid becomes multimerized, the number of units distributable to daughter cells drops and cells without plasmid are more easily obtained. Indirectly therefore, the cer stabilizes the plasmid by maintaining it in the state of monomer.
  • the present invention also relates to plasmid vectors which further comprise the gene coding for a protein of industrial interest and the elements ensuring its expression in the host bacterium, and, in particular, the gene coding for a hirudin or the one of its natural or synthetic variants, C2, 3O, gamma interferon or alpha antitrypsin for example, as well as the transformed strains by these various vectors and the processes for preparing industrial proteins by culture of said transformed strains on complete medium and recovery of the protein after culture.
  • the expression system comprises the left promoter of phage lambdaP L , but it could be another promoter active in the bacteria in question. This explains why there will not be a complete description of the elements of expression of the heterologous protein, this type of plasmid is now widely known. It will simply be necessary to insert the dapD or other gene into a nonessential site of the plasmid vector.
  • the plasmids in question can be used to transform any E. coli strain made dapD ⁇ .
  • bacterial strains are obtained in which the expression plasmids are stable in a complete medium without the need for selective pressure by an antibiotic or a particular medium lacking an amino acid for example.
  • the method according to the invention exerts a counter-selection against the bacteria which have lost the plasmid.
  • the invention also relates to a process for the preparation of a protein of industrial interest from a bacterium, in which a bacterium is cultivated in particular according to the invention, and said protein is recovered.
  • plasmids carrying the dapD gene have also been used to express the genes coding for hirudin and gamma interferon.
  • thermosensitive repressor CI857 This system makes it possible to induce the expression of the gene controlled by P L by raising the temperature.
  • the strain of E. coli TGE 900 which includes the repressor CI857 was modified to become dapD ⁇ by giving the strain TGE 7615 or TGE7214 and the strain N 5969 was modified to become TGE7303.
  • the competent cells were prepared according to the method of Hanahan (1983). Their competence amounts to 104 to 105 transformants / ⁇ g DNA for the RL58 strain (Bollen et al. 1979) and 105 to 106 transformants / ⁇ g DNA for the TGE7615, TGE7214 or TGE 7303 strains.
  • a stock of competent cells is added 1 to 10 ⁇ l of a solution having the appropriate dilution, of a DNA preparation containing the plasmid which it is desired to introduce into the strain. .
  • the cells are allowed to react with the DNA for 15 minutes at 0 ° C and then incubated at 37 ° C for 90 seconds. They are returned to 0 ° C for 5 minutes and then 0.8 ml of LB medium is added thereto.
  • this medium must contain DAP at a rate of 8 gamma / ml. This is necessary for the growth of dapD ⁇ cells, even those which contain the plasmid carrying the dapD gene.
  • the cells are generally incubated at 30 ° C with vigorous shaking (however, they can be put at 37 ° C if the plasmid does not contain the P L promoter).
  • the incubation time is 60 minutes, but it can be extended to 90 minutes for growth at 30 ° C. for the strain TGE 7615.
  • the clones are selected by adding 100 gamma / ml of ampicillin; the clones containing the dapD gene are selected, from a culture which is dapD ⁇ as a whole, on the LB medium without other additions.
  • the dishes are incubated for 24 hours at 30 ° C.
  • the colonies are then subcultured with a toothpick in 3 ml of LB medium and after overnight growth at 30 ° C. the plasmid is isolated and its structure confirmed on agarose gel, after digestion with the appropriate restriction enzymes.
  • the plasmids containing the dapD gene can be transformed into any E. coli which carries the dapD ⁇ mutation (for example RL58, TGE7615, TGE7214 or TGE7303); if, in addition, they contain the promoter P L of the bacteriophage lambda, they must necessarily be transformed into strains of E. coli dapD ⁇ which express the repressor C1857 of the bacteriophage lambda, either on a plasmid or in a chromosome, or the Cl and a Rec mutation (for example RecA441).
  • E. coli which carries the dapD ⁇ mutation for example RL58, TGE7615, TGE7214 or TGE7303
  • they contain the promoter P L of the bacteriophage lambda they must necessarily be transformed into strains of E. coli dapD ⁇ which express the repressor C1857 of the bacteriophage lambda, either on a plasmid or in a chromos
  • the host strain E. coli TGE900 was made dap ⁇ by conjugation with a known dapD ⁇ mutant, RL58.
  • the TGE900 strain is a derivative of the N4830 strain described by Gottesman et al. (1980) whose characteristics are: su ⁇ F ⁇ his ilv bio ( ⁇ cI857 ⁇ Bam ⁇ HI) Sm r . It is commonly used as a host for expression vectors in which the foreign gene is placed under the control of the P L lambda promoter because it makes it possible to induce expression at will by increasing the temperature (greater than 37 ° C) which inactivates the heat-sensitive repressor (lambda cI857) carried by the bacteria.
  • the dap ⁇ RL58 strain (met B dapD2 met D279 Hfr P4 X) has been described by Bollen et al. (1979).
  • a spontaneous mutant resistant to trimethoprim was selected (after spreading the strain on a dish containing 2 gamma / ml of trimethoprim and confirmation of the resistant character of a colony chosen in the medium containing 4 gamma / ml of trimethoprim ).
  • the gene coding for this resistance is sufficiently close to the dapD ⁇ mutation so that if the receptor strain after conjugation becomes resistant to trimethoprim it has also become dapD ⁇ .
  • the resistant strain was called TGE755; its useful characteristics are Hfr dapD ⁇ Tmp r .
  • the construction was started from the plasmid pML2 (Lusky and Botchan, 1981), derived from pBR322 by deletion of nucleotides 1089 to 2491. This plasmid retained the origin of replication of pBR322 and the beta lactamase gene (resistance to ampicillin).
  • the recognition sequence of the PstI enzyme was eliminated by insertion of an AhaIII-AhaIII fragment from pUC8 which carries an ethane sulfonate-induced PstI ° mutation (Vieira and Messing, 1982), between two AhaIII sites of pML2 , which deletes 19 base pairs from pML2.
  • the resulting plasmid, pTG190 carries the PstI ° mutation from pUC8.
  • PTG191 was opened by EcoRI and BglII (which deletes the tetracycline resistance gene) and religated with the EcoRI-BglII segment of phage M13TG131 (Kieny et al., 1983) which comprises a polylinker with 12 recognition sequences d restriction enzymes.
  • the resulting plasmid is pTG192.
  • the chromosomal gene dapD from E. coli was inserted into the plasmid pACYC184 to give pDB6 (Bendiak and Friesen, 1981).
  • This dapD gene was recovered from pDB6 in the form of a 1.3 kb AluI fragment and inserted into the EcoRI site of pTG192 (the EcoRI ends having previously been repaired by treatment with the Klenow fragment of DNA polymerase I ).
  • pTG764 is chosen in which a single EcoRI site is reconstituted. pTG764 therefore carries the dapD gene and the ampicillin resistance gene from pTG192 (originally from pUC8).
  • the plasmid pTG720 described in French patent n ° 84 04755 essentially comprises the hirudin gene under the control of the P L lambda promoter.
  • the plasmid pTG720 digested with BglII and BglI gives a 2.74 kb fragment which carries the hirudin gene and part of the amp r gene.
  • This phosphatase-treated fragment is religated to the BglII-BglI fragment of the plasmid pTG764 which carries the dapD gene and another fragment of the amp r gene.
  • the resulting plasmid, pTG771 carries the reconstituted full amp r gene, the dapD gene and the gene coding for hirudin.
  • the colonies of TGE7615 transformed by this plasmid can be selected either on LB medium (selection for the dap+ character) or on LB medium + ampicillin.
  • the transformed strain After induction, the transformed strain produces hirudin.
  • the starting plasmid is pTG771.
  • Plasmid pTG776 is obtained.
  • the TGE7615 bacteria transformed by this plasmid can be selected in LB medium, without addition (selection for the dap+ character).
  • the transformed strain After induction, the transformed strain produces hirudin.
  • the starting plasmid is the plasmid pTG192.
  • the vector fragment of 0.95 kb is isolated and ligated with the AluI fragment of 1.3 kb of pDB6 which carries the dapD gene.
  • the amp r gene has therefore been completely deleted.
  • the strain TGE7615 is transformed with this new plasmid and selected on LB medium to obtain clones which carry the dapD gene.
  • the TGE7615 bacteria transformed by these plasmids can be selected in LB medium, without addition (selection for the dap+ character).
  • the transformed strain After induction, the transformed strain produces gamma interferon.
  • the plasmids which contain the dapD gene see their increased stability compared to the plasmids carrying the amp r gene and their loss becomes minimal.
  • p- / cell / generation has lost its significance under such conditions since the p + no longer multiply.
  • Fp- the percentage of cells in the culture and estimate the degree of contamination of the culture by p- cells at all times.
  • Fp- is an objective parameter which makes it possible to decide whether a culture intended for the production of a molecule is sufficiently pure to be worth a further development and which makes it possible to compare different plasmids with one another under the conditions of induction.
  • TGE900 / pTG720 Typical results for TGE900 / pTG720 are shown in Table 3.
  • Table 3 Plasmid stability parameter during expression at 42 ° C of hirudin in TGE900 / pTG720 Time in hours c / ml / DO % p + p- / ml / DO Fp- (%) 0 h 8.3.107 100 ⁇ 1.7.106 ⁇ 0.4 1 h 30 2,4.108 100 ⁇ 4.8.106 ⁇ 1.2 3 hrs 2.1.108 96 8.4.106 2.1 4:30 a.m. 4.7.107 82 8.5.106 2.1 5:30 a.m. 1.8.107 48 9.4.106 2.35 7 a.m. 2.8.107 20 2.2.107 5.5
  • Plasmids pTG720 and pTG771 were isolated at different times during induction. Generally, at the start of induction, in the exponential phase, there is a weak plasmid content per cell which increases appreciably over time. During this same period, hirudin is produced.
  • the hirudin activities produced from pTG720 or pTG771 are not significantly different.
  • the values (in antithrombin units, UAT) are 2720 UAT / l / DO for pTG720 and 2380 UAT / l / DO for pTG771, after 5 hours of induction.
  • pTG771 shows an increased stability compared to pTG720, while keeping the same production capacity and the same properties of increasing its number of copies at the end of the exponential phase as pTG720.
  • PTG7671 retains the same capacity to produce gamma interferon as the original plasmid pTG40.
  • Example 10 Deletion of the dapD gene from the chromosome of the bacteria.
  • the plasmid pDB6 and M13mp8 are cut by PstI and ligated.
  • the M13 containing the 5 ′ end and the 3 ′ end of the gene are screened with oligonucteotides specific for these regions, respectively TG596 (GCGCTTAATAACGAGTTG) and TG598 (TGTGCATACTTTAGTC).
  • the candidates SB96 and SB98 are retained and the insertion of the desired fragments confirmed by sequencing. (see diagram in Figure 6).
  • the kanamycin resistance gene from the plasmid pUC-4K (sold by Pharmacia) is recovered in the form of an EcoRI fragment.
  • the M13TG597 and 620 are cut by EcoRI and PstI which releases the 3 'end of the dapD gene (without the supposed terminator) and the 5' end of the gene (with its supposed promoter) respectively.
  • the cloning vector pTG192 (described in Example 2a) is cut with PstI.
  • pTG47 A construction has been selected: pTG47. Its structure is analyzed by DNA mini-preparation and the orientation of the kanamycin resistance gene and determined by digestion of the plasmid with HindIII, which releases 2 bands of sizes 5.3 and 4.0 kb. The orientation of the kanamycin resistance gene in pTG47 is the same as that of the dapD gene in pDB6 (in the other orientation we would have obtained bands of sizes 4.9 and 4.4 kb). The diagram for pTG47 is shown in Figure 8.
  • RH5345 cells the competence of which is 2.5 10 ⁇ 7 transformants / ⁇ g of pTG47 DNA, are transformed by the plasmid pTG47 previously cut by KnpI and BglII (see FIG. 8). This digestion releases a fragment which contains the flanking regions of the dapD gene, the gene itself being replaced by the kanamycin resistance gene.
  • the dapD deletion of the strain TGE721 is then transduced into the strains TGE901 and N5969 by the transducing phage Plvir / TGE721 and the dap ⁇ recombinants selected by their resistance to 0.01 ⁇ g / ml of kanamycin.
  • the successful candidates are TGE7213, 7214 and TGE7303 respectively.
  • the requirements in ile, val, his of the mother strain, TGE901, in addition to the character dap ⁇ kan R have been confirmed on the appropriate media, for a candidate: TGE7214.
  • chromosomal DNAs of GC4540, TGE7213, 7214 and TGE901 are compared with, as controls M13TG620, M13TG597, the BamHI-HindIII fragment of pDB6 and the same fragment cut by PstI (FIG. 6).
  • the chromosomal DNAs are cut by PstI or BamHI and HindIII.
  • M13TG620 cut by EcoRI is isolated from the band specifically containing the 5 ′ side of the dapD gene for use as a probe (FIG. 9B).
  • the probe is pTG47 cut by KpnI and BglII. This probe should light, in addition to the bands predicted above, at least one band of 1.7 kb. In fact, pTG47 contains 300 bp and 100 bp homologous to the dapD gene, on the 5 ′ side and on the 3 ′ side respectively, and which should light up in the deleted strains.
  • the cer gene is recovered from the plasmid ColE1, the sequence of which was published by Chan et al. (1985), in the form of a 1.85 kb HaeII fragment.
  • the HaeII fragment is then cut with HpaII, treated with Klenow and a 0.4 kb band is recovered.
  • the M13mp130 is cut with EcoRV and treated with phosphatase.
  • the 0.4 kb fragment of ColE1 is ligated into the M13mp130 and it is introduced into the strain JM103.
  • the presence of the cer fragment of ColE1 was confirmed by sequencing the 0.4 kb band released by SmaI and HindIII cleavage.
  • the cer gene inserted into the polylinker of M13mp131 is then isolated after digestion with SmaI and HindIII and ligated into the vector pTG720 (carrying the hirudin gene, FIG. 2) cut with BglII and treated with Klenow.
  • the resulting plasmid is pTG720cer.
  • Example 13 Construction of cloning vectors containing the cer gene and the dapD gene.
  • PTG192 (FIG. 1) is cut with EcoRI and BglII to release the polylinker from M13mp131 and is shortened by HaeIII digestion.
  • a plasmid carrying the ampicillin resistance gene is used, for example pTG730 (hirudin expression vector described in French patent 86.16723); this plasmid is cut with BglII and EcoRI and ligated to the EcoRI-BglII fragment of pTG192. In this way, the expression block comprising P L and the hirudin structural gene of pTG730 is lost, which is replaced by the polylinker of M13mp131. This new plasmid is called pTG790 ( Figure 10).
  • PTG790 is cut with SstI and KpnI and treated with phosphatase.
  • the fragment resulting from this digestion is ligated to pTG720cer, cut with SstI and KpnI (which releases the cer fragment) and shortened by BglII digestion.
  • the resulting vector, pTG792 contains the cer fragment ( Figure 11).
  • PTG792 is cut with EcoRI, treated with Klenow and phosphatase. The resulting fragment is ligated with the 1.3 kb AluI fragment from pDB6 which contains the dapD gene (FIG. 6). This results in 2 plasmids pTG7922 and pTG7923 which differ only in the orientation of the dapD gene located between 2 EcoRI sites. For pTG7922, the promoters of the 3 genes, origin of replication, resistance to ampicillin and dapD are oriented in the same way (FIG. 12).
  • a PstI fragment of pTG7922 and pTG7923 containing the 3 ′ and 5 ′ part of the dapD gene and the cer gene are respectively recovered to introduce it into a dap vector containing an analogous fragment but no EcoRI or AvaI site, nor the cer .
  • the analogous vectors are respectively pTG767 and pTG766 described above.
  • PTG7922 and pTG7923 are cut by PstI, shortened by BglII digestion and ligated respectively in pTG767 and pTG766 cut by PstI and treated with phosphatase.
  • the resulting cloning vectors are pTG769 and pTG768 respectively (pTG769 is shown in Figure 13).
  • the C 2.3 O structural gene is recovered from pTG444 to be introduced into the dap vector pTG7671 (described previously).
  • PTG444 is identical to pTG445 described by Zukowski et al. (1984) with the exception of an unregenerated XmaIII site.
  • PTG444 is cut with BamHI and HindIII and ligated to pTG769 cut with BamHI and HindIII and treated with phosphatase.
  • the resulting plasmid, called pTG7401 contains the C 2,3 O structural gene.
  • PTG7671 contains 2 BglII sites: a site upstream of P L forming part of the polylinker and a site downstream of P L located in the ribosome attachment site, upstream of the structural gene of gamma interferon.
  • PTG7671 is cut by BglII and shortened by KpnI digestion. The resulting mixture is ligated into pTG7401 cut in its polylinker with BglII and BamHI and treated with phosphatase. By this ligation, the BglII site is reconstituted, but the BamHI site ligated to BglII is lost. Two orientations of P L with respect to the C 2,3 O structural gene are possible.
  • the retained plasmid, pTG7407, having C 2.3 O under the control of P L has a structure similar to pTG7406 described below (compare in FIG. 14) but it has lost the BamHI site upstream of C 2.3 O.
  • PTG769 is cut with BglII and BamHI, treated with phosphatase and ligated with a BamHI-BglII fragment of any expression plasmid (pTG907) which contains the P L and the complete N gene, of ⁇ .
  • pTG7400 which can be identified by a BamHI and BglII cut which releases 2 bands: at 2.6 kb and 1.3 kb. This construct contains the P L and the complete N gene.
  • the pTG7400 is then cut with HpaI and a BamHI linker (sold by BRL) CCGGATCCGG, phosphorylated and hybridized, is inserted therein. This gives pTG7402 which has lost its HpaI site but contains 2 BamHI sites.
  • PTG7402 is cut with BamHI and religated to give pTG7404.
  • pTG7404 By this manipulation, a BamHI site was eliminated and the N gene was truncated.
  • the pTG7402 is cut with BamHI and HindIII, treated with phosphatase and the BamHI-HindIII fragment of pTG444 is introduced therein to give pTG7406 (see FIG. 14). It differs from pTG7407 in that the C 2.3 O gene can be removed by a BamHI, HindIII cleavage to recover the fragment introduced from pTG444.
  • the expression of the C 2,3 O gene in TGE7213 / pTG7407 bacteria was measured at 30 ° C after 4 h and 7 h of culture and during the induction at 42 ° C after 4 h and 7 h. For each determination, a sample of the culture is collected and centrifuged; the pellet is washed and taken up in phosphate buffer (as described by Zukowski et al. 1983) then treated with ultrasound for 3 times 20 seconds. After centrifugation 10 min. at 10,000 g, the pellet is considered as the insoluble fraction (C) and the supernatant as the soluble fraction (S).
  • the proteins present in each fraction are analyzed by electrophoresis on polyacrylamide-SDS gel.
  • the bands are revealed by coloring with Coomassie blue.
  • the results are presented in FIG. 15.
  • the intensity of the PM 35,000 band is noted, in particular after 7 h of induction at 42 ° C.
  • the scanning of the gel gives approximately 64% and 75% of C 2.3 O in the S and C fractions respectively.
  • the pTG7671 described above is cut at the level of its polylinker with SstI (identical to SacI) and KpnI then treated with phosphatase and ligated to the fragments of pTG720cer cut with SstI and KpnI.
  • SstI identical to SacI
  • KpnI treated with phosphatase and ligated to the fragments of pTG720cer cut with SstI and KpnI.
  • TGE7615 a candidate, pTG7675, is retained which releases 2 fragments of 400 bp and 3.4 kb after digestion with SstI and KpnI (FIG. 16).
  • Example 16 Demonstration of the Plasmid Stability During the Induction of the Expression of Gamma Interferon.
  • the results are shown in Table 9.
  • the total cells / ml / unit of OD are measured to determine that the loss of viability is a real phenomenon and not a change in cell volume, for example. These data are also shown in Table 9.
  • the Fp ⁇ was defined in Example 7 and relates the number of p ⁇ cells to the total number of cells present at a given time.
  • the Fph30 after 7:30 of induction reaches a value of almost 2%. It is therefore lower than in the previous experiment (see example 9), which can only be attributed to a difference in the structure of the plasmid pTG40 in these 2 experiments: indeed, although the quantity of plasmid is equivalent at different times of induction, in the first experiment the plasmid was in dimeric form whereas in the experiment described here it is mainly in monomeric form (as shown by a gel analysis). The state of the plasmid does not influence the production of gamma interferon but concretely illustrates the loss of stability if the monomeric form of a plasmid is not maintained.
  • the plasmid content has the same characteristics as before, that is to say an increase in the number of copies at the end of growth but the multimeric forms present in more or less number with the plasmids without cer, are almost absent here.
  • the production of gamma interferon is slightly higher than that obtained with pTG40.
  • Example 17 Application of the dap model to the construction of an expression vector for alpha-1 antitrypsin.
  • the PstI fragment containing the expression block of alpha-1 antitrypsin that is to say the P L promoter of phage lambda, the truncated N gene, a ribosome attachment site and the structural gene for l alpha-1 antitrypsin (Arg358) from pTG2901 (truncated derivative of pTG983, described in French patent 85.07393) is introduced into pTG792 (described above) cut with PstI and treated with phosphatase.
  • the resulting expression vector, pTG7913 is then cut with BglII and SstI and the expression block containing alpha-1 antitrypsin and the cer gene is introduced into pTG767 cut with BglII and SstI and treated with phosphatase.
  • the resulting plasmid, pTG7914 contains the dapD gene, the cer gene and the expression block for alpha-1 antitrypsin (Arg358) (FIG. 17).

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP87401815A 1986-08-05 1987-08-05 Procédé de stabilisation d'un plasmide contenu dans une souche bactérienne et souche obtenue Expired - Lifetime EP0258118B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR8611311A FR2602792B1 (fr) 1986-08-05 1986-08-05 Procede de stabilisation d'un plasmide contenu dans une souche bacterienne et souche obtenue
FR8709935A FR2618159B2 (fr) 1987-07-15 1987-07-15 Procede de stabilisation d'un plasmide contenu dans une souche bacterienne et souche obtenue
FR8709935 1987-07-15
FR8611311 1987-07-15

Publications (2)

Publication Number Publication Date
EP0258118A1 EP0258118A1 (fr) 1988-03-02
EP0258118B1 true EP0258118B1 (fr) 1995-10-18

Family

ID=26225423

Family Applications (1)

Application Number Title Priority Date Filing Date
EP87401815A Expired - Lifetime EP0258118B1 (fr) 1986-08-05 1987-08-05 Procédé de stabilisation d'un plasmide contenu dans une souche bactérienne et souche obtenue

Country Status (9)

Country Link
EP (1) EP0258118B1 (da)
JP (3) JP2772793B2 (da)
AT (1) ATE129285T1 (da)
AU (1) AU616637B2 (da)
CA (1) CA1340903C (da)
DE (1) DE3751564T2 (da)
DK (1) DK408687A (da)
ES (1) ES2079348T3 (da)
GR (1) GR3018296T3 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE121785T1 (de) * 1987-10-07 1995-05-15 Univ Washington Verfahren zur erhaltung eines erwünschten rekombinanten gens in einer genetischen zellpopulation.
JP3078312B2 (ja) * 1990-11-22 2000-08-21 協和醗酵工業株式会社 物質の製造法
TW201794B (da) * 1991-05-03 1993-03-11 American Cyanamid Co
GB9605453D0 (en) * 1996-03-15 1996-05-15 Univ Cambridge Tech Cultured cells
US6291245B1 (en) * 1998-07-15 2001-09-18 Roche Diagnostics Gmbh Host-vector system
EP0972838B1 (en) * 1998-07-15 2004-09-15 Roche Diagnostics GmbH Escherichia coli host/vector system based on antibiotic-free selection by complementation of an auxotrophy
US6872547B1 (en) * 2000-10-11 2005-03-29 Washington University Functional balanced-lethal host-vector systems
DE102004040134A1 (de) * 2004-08-19 2006-02-23 Henkel Kgaa Neue essentielle Gene von Bacillus licheniformis und darauf aufbauende verbesserte biotechnologische Produktionsverfahren
JP5415763B2 (ja) * 2005-10-06 2014-02-12 ドムペ・ファ．ル．マ・ソチエタ・ペル・アツィオーニ 新規選択系
US10829508B2 (en) 2015-12-18 2020-11-10 Glycom A/S Fermentative production of oligosaccharides

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2511032B1 (fr) * 1981-08-07 1985-08-09 Centre Nat Rech Scient Nouveaux plasmides et souches bacteriennes transformees et leur application a la synthese de lysine
FR2520753B1 (fr) * 1982-02-01 1986-01-31 Transgene Sa Nouveaux vecteurs d'expression de la catechol 2,3-oxygenase, enzymes obtenues et leurs applications
DK410783D0 (da) * 1982-09-16 1983-09-09 Benzon A Salfred Fremgangsmade til stabilisering af plasmider
FR2556365B1 (fr) * 1983-12-09 1987-07-31 Transgene Sa Vecteurs de clonage et d'expression de l'interferon-g, bacteries transformees et procede de preparation de l'interferon-g
WO1985004418A1 (fr) * 1984-03-27 1985-10-10 Transgene S.A. Vecteurs d'expression de l'hirudine, cellules transformees et procede de preparation de l'hirudine
DE3581328D1 (de) * 1984-06-19 1991-02-21 Transgene Sa Derivate des menschlichen alpha-1-antitrypins und verfahren zu deren herstellung.
DK594084A (da) * 1984-12-12 1986-06-13 Novo Industri As Fremgangsmaade til stabilisering af extra-chromosomale elementer i bakterier under dyrkning
GB2177097A (en) * 1985-06-18 1987-01-14 Genencor Inc Stable maintenance of nucleic acid in recombinant cells

Also Published As

Publication number Publication date
DK408687A (da) 1988-02-06
GR3018296T3 (en) 1996-03-31
JP2844191B2 (ja) 1999-01-06
JPS63233790A (ja) 1988-09-29
JPH104981A (ja) 1998-01-13
JP2905921B2 (ja) 1999-06-14
AU7658987A (en) 1988-02-11
AU616637B2 (en) 1991-11-07
JPH1066575A (ja) 1998-03-10
DE3751564D1 (de) 1995-11-23
CA1340903C (fr) 2000-02-22
EP0258118A1 (fr) 1988-03-02
JP2772793B2 (ja) 1998-07-09
ATE129285T1 (de) 1995-11-15
ES2079348T3 (es) 1996-01-16
DK408687D0 (da) 1987-08-05
DE3751564T2 (de) 1996-03-28

Similar Documents

Publication Publication Date Title
EP0597035B1 (fr) Levures recombinantes hautement stables pour la production de proteines recombinantes
Conway et al. Cloning and sequencing of the alcohol dehydrogenase II gene from Zymomonas mobilis
de Zamaroczy et al. Functional organization of the glnB-glnA cluster of Azospirillum brasilense
KR20130117753A (ko) 포스포케톨라아제를 포함하는 재조합 숙주 세포
FR2821855A1 (fr) Genes synthetiques et plasmides bacteriens depourvus de cpg
EP0258118B1 (fr) Procédé de stabilisation d'un plasmide contenu dans une souche bactérienne et souche obtenue
KR19990044525A (ko) 플라스미드의 안정화
EP0599971B1 (fr) Promoteur de levure et son utilisation
JP3593125B2 (ja) 染色体に組込まれた異種遺伝子を高度に発現する組換え細胞
EP0631626B1 (fr) Plasmide thermosensible
US5198343A (en) Method for expressing a heterologous protein in a dapD- mutant of E. coli and the strain obtained
EP0511108A1 (fr) Nouvelles souches de levure de panification et leur procédé d'obtention, nouvelles levures fraîche et sèche correspondantes
EP1664305B1 (en) Selection system containing non-antibiotic resistance selection marker
Cerdan et al. Oxygen-dependent upstream activation sites of Saccharomyces cerevisiae cytochrome c genes are related forms of the same sequence
FR2552102A1 (fr) Vecteurs constitues par des plasmides a taux de replication eleve, leur production et leur utilisation
Akanuma et al. Spontaneous tandem sequence duplications reverse the thermal stability of carboxyl-terminal modified 3-isopropylmalate dehydrogenase
EP0771872A1 (fr) Procédé de polymèrisation de séquences d'acides nucléiques et ses applications
FR2602792A1 (fr) Procede de stabilisation d'un plasmide contenu dans une souche bacterienne et souche obtenue
EP1029063B1 (fr) Plasmide de leuconostoc non rcr apte a etre transfere dans des bacteries lactiques; utilisation comme outil de clonage et d'expression
JP3910248B2 (ja) トランスポゼースを用いるｉｎ ｖｉｔｒｏ反応によるＤＮＡ入れ子型欠失の作製方法
FR2618159A2 (fr) Procede de stabilisation d'un plasmide contenu dans une souche bacterienne et souche obtenue
US20020123100A1 (en) Binary BAC vector and uses thereof
EP0261009A1 (fr) Sequence d'ADN exercant une fonction se manifestant par une surproduction de protéines exocellulaires par diverses souches de bacillus, et vecteurs contenant cette séquence
FR2629097A1 (fr) Sequence d'adn comprenant la partie fonctionnelle du locus sacu de b. subtilis, vecteurs contenant la sequence correspondante, et leur utilisation dans des procedes de production de proteines
HK1084975B (en) Selection system containing non-antibiotic resistance selection marker

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

17P Request for examination filed

Effective date: 19880829

17Q First examination report despatched

Effective date: 19930128

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: TRANSGENE S.A.

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

REF Corresponds to:

Ref document number: 129285

Country of ref document: AT

Date of ref document: 19951115

Kind code of ref document: T

GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)

Effective date: 19951016

REF Corresponds to:

Ref document number: 3751564

Country of ref document: DE

Date of ref document: 19951123

ITF It: translation for a ep patent filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2079348

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: GR

Ref legal event code: FG4A

Free format text: 3018296

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20020716

Year of fee payment: 16

Ref country code: NL

Payment date: 20020716

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20020717

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20020726

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20020730

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20020806

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20020808

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20020812

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20020822

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20020829

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20020903

Year of fee payment: 16

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030805

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030805

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030805

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030806

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030806

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030831

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030831

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030831

BERE Be: lapsed

Owner name: S.A. *TRANSGENE

Effective date: 20030831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040302

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040303

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20030805

EUG Se: european patent has lapsed
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040430

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20040301

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20030806

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050805